Yestar Healthcare Holdings Co Ltd (2393) AI Stock Analysis

• Market Cap: HK$298.19M
• Dividend Yield: N/A
• Average Volume (3M): 2.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 6.10%
• EPS Growth: -115.12%
• Country: HK
• Employees: 627
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): <0.01
• Shares Outstanding: 2,331,590,000
• 10 Day Avg. Volume: 1,184,000
• 30 Day Avg. Volume: 2,342,546
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.29
• Price to Sales (P/S): 0.06
• P/FCF Ratio: -5.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: HK$0.12 ▼(-1.67% Downside)

Yestar Healthcare Holdings is currently facing significant financial and operational challenges, reflected in its low financial performance score. The technical analysis indicates bearish momentum, and the valuation metrics suggest financial distress. These factors collectively result in a low overall stock score.

Positive Factors

Market Position

Yestar's leadership in medical imaging and IVD products positions it well in a growing healthcare sector, supporting long-term demand.

Revenue Streams

Diverse revenue streams from imaging and IVD products provide stability and growth potential, reducing reliance on a single product line.

Partnerships

Strategic partnerships enhance product offerings and market reach, fostering innovation and competitive advantage in the healthcare market.

Negative Factors

Financial Challenges

Ongoing financial struggles, such as declining revenues and profitability, threaten long-term sustainability and require strategic intervention.

Balance Sheet Health

Negative equity and high leverage indicate financial distress, limiting the company's ability to invest in growth and manage economic downturns.

Cash Flow Issues

Inconsistent cash flow and negative free cash flow limit financial flexibility, hindering the company's ability to fund operations and growth initiatives.

Yestar Healthcare Holdings Co Ltd Business Overview & Revenue Model

Company Description

Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. It operates through two segments, Imaging Printing Products, and Medical Products and Equipment. The Imaging Printing Products segment manufactures and sells Fujifilm color photographic paper, industrial NDT X-ray films, and PWB films; and trades in imaging equipment. Its products are used in professional and minilabs; and industrial imaging applications. This segment provides NDT X-ray films under the Yes!Star brand. The Medical Products and Equipment segment manufactures and sells medical dry and wet films, and dental films; and sells medical equipment and diagnostic reagents. The company also distributes in vitro diagnostic products. In addition, it engages in the biotechnology development activities; management of supply chain activities; and provision of freight transportation services. The company was formerly known as Yestar International Holdings Company Limited and changed its name to Yestar Healthcare Holdings Company Limited in January 2017. Yestar Healthcare Holdings Company Limited was founded in 1971 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Yestar Healthcare Holdings generates revenue through multiple key streams. Primarily, the company earns income from the sale of its medical imaging equipment and diagnostic devices to hospitals and healthcare facilities. Additionally, Yestar provides diagnostic imaging services, such as MRI, CT scans, and ultrasound services, which contribute significantly to its revenue. The company also capitalizes on partnerships with hospitals and healthcare providers by offering integrated healthcare solutions and management services, allowing for a recurring revenue model through service contracts and maintenance agreements. Furthermore, Yestar is expanding its digital healthcare initiatives, which include telemedicine services and health information technology, potentially creating new avenues for revenue generation as the demand for remote healthcare services continues to grow.

Yestar Healthcare Holdings Co Ltd Financial Statement Overview

Summary

Yestar Healthcare Holdings is facing significant financial challenges, including declining revenues, deteriorating profitability, high leverage, and inconsistent cash flow generation. The balance sheet is weak with negative stockholders' equity, and cash flow performance is poor with negative free cash flow.

Income Statement

Yestar Healthcare Holdings has experienced significant revenue volatility with a declining trend from 2019 to 2024. The gross profit margin has deteriorated from 25.8% in 2019 to 16.6% in 2024, indicating reduced profitability. The net profit margin has shown improvement, turning positive in 2024, but is largely due to a significant one-time gain rather than operational performance. EBIT and EBITDA margins have also decreased, reflecting operational challenges.

Balance Sheet

The company has a weak balance sheet characterized by negative stockholders' equity in recent years, indicating potential financial distress. The Debt-to-Equity ratio is not meaningful given the negative equity, suggesting high leverage. Despite a positive shift in equity in 2024, the overall financial stability remains questionable with a low equity ratio.

Cash Flow

Cash flow performance has been inconsistent, with operating cash flow declining from 2020 to 2024 and free cash flow turning negative. The operating cash flow to net income ratio is not meaningful for 2024 due to zero operating cash flow. The company has struggled to generate sustainable free cash flow, impacting its financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.94B	2.41B	2.91B	2.80B	4.93B	4.11B
Gross Profit	315.30M	399.20M	512.78M	397.55M	848.70M	806.88M
EBITDA	-78.16M	-51.93M	376.81M	19.13M	315.89M	305.49M
Net Income	-161.86M	921.61M	-13.89M	-992.23M	3.33M	-590.49M
Balance Sheet
Total Assets	1.36B	1.43B	3.43B	3.37B	4.56B	4.66B
Cash, Cash Equivalents and Short-Term Investments	249.36M	151.78M	251.56M	418.15M	751.77M	625.20M
Total Debt	281.42M	316.90M	1.63B	1.90B	1.79B	1.84B
Total Liabilities	839.91M	921.84M	3.82B	3.71B	3.73B	3.80B
Stockholders Equity	469.65M	461.60M	-457.50M	-408.87M	755.23M	757.04M
Cash Flow
Free Cash Flow	239.65M	-26.45M	294.22M	-115.58M	665.55M	591.92M
Operating Cash Flow	272.74M	12.72M	387.67M	-91.73M	715.22M	670.73M
Investing Cash Flow	-31.65M	380.42M	-89.82M	-18.72M	-47.67M	-37.21M
Financing Cash Flow	-124.65M	-502.63M	-234.37M	-180.86M	-654.20M	-604.74M

Yestar Healthcare Holdings Co Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2393, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.13, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.65 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2393.

Yestar Healthcare Holdings Co Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	79 Outperform	HK$6.73B	14.69	8.59%	2.65%	13.59%	6.31%
1612	67 Neutral	HK$540.42M	6.03	14.73%	5.06%	17.93%	36.82%
1696	60 Neutral	HK$1.95B	12.17	4.46%	3.02%	-3.32%	-12.94%
6118	52 Neutral	HK$553.59M	14.59	4.40%	―	-2.77%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2170	44 Neutral	HK$588.08M	―	-20.60%	―	11.43%	4.88%
2393	40 Underperform	HK$298.19M	-1.73	-29.79%	―	6.10%	-115.12%

Yestar Healthcare Holdings Co Ltd Corporate Events

Yestar Healthcare Plans Joint Venture to Expand Precision Oncology Services in Southeast Asia

Yestar Healthcare Holdings Co Ltd has announced plans to form a joint venture in Singapore with New Genetron Holding Limited, focusing on establishing clinical molecular diagnostics laboratories in Indonesia. The venture aims to advance precision oncology by offering services like early cancer screening and comprehensive genomic profiling, leveraging Genetron Health’s technology. This strategic move is expected to enhance Yestar’s market presence in Southeast Asia and foster partnerships with Indonesian healthcare institutions, potentially impacting the company’s operational scope and industry positioning.

Yestar Healthcare’s Controlling Shareholder Releases Pledged Shares

Yestar Healthcare Holdings Co Ltd announced that its controlling shareholder, Mr. Hartono James, has fully repaid a loan secured by a pledge of company shares. Consequently, the pledged shares will be released, indicating a positive step towards financial stability and potentially impacting shareholder confidence.

Yestar Healthcare Reports Significant Decline in Interim Profits

Yestar Healthcare Holdings Co Ltd announced its unaudited interim results for the six months ending June 30, 2025. The company reported a significant decrease in revenue and profit compared to the same period in 2024, with revenue dropping from RMB 1,273,785,000 to RMB 802,634,000 and profit before income tax falling from RMB 1,112,323,000 to RMB 21,152,000. The results indicate a challenging period for the company, impacting its financial performance and potentially its market positioning.

Yestar Healthcare Schedules Board Meeting to Review Interim Results

Yestar Healthcare Holdings Co Ltd has announced a board meeting scheduled for August 29, 2025, to review and approve the unaudited consolidated interim results for the first half of 2025. The meeting will also consider the declaration of an interim dividend, which could have implications for the company’s financial strategy and shareholder returns.

Yestar Healthcare Issues Profit Warning Amid Revenue Decline

Yestar Healthcare Holdings Co Ltd has issued a profit warning, indicating a substantial decrease in net profit for the first half of 2025 compared to the same period in 2024. The decline is attributed to the absence of a one-time profit from senior notes redemption and reduced revenue from its medical products segment. The company advises caution to shareholders and potential investors as it finalizes its unaudited results, with a detailed announcement expected by the end of August 2025.